127 related articles for article (PubMed ID: 23744431)
1. In vivo and ex vivo responses of CLL cells to purine analogs combined with alkylating agent.
Żołnierczyk JD; Borowiak A; Błoński JZ; Cebula-Obrzut B; Rogalińska M; Kotkowska A; Wawrzyniak E; Smolewski P; Robak T; Kiliańska ZM
Pharmacol Rep; 2013; 65(2):460-75. PubMed ID: 23744431
[TBL] [Abstract][Full Text] [Related]
2. Relationship between in vitro drug sensitivity and clinical response of patients to treatment in chronic lymphocytic leukemia.
Rogalińska M; Błoński JZ; Góralski P; Wawrzyniak E; Hartman M; Rogalska A; Robak P; Koceva-Chyła A; Piekarski H; Robak T; Kiliańska ZM
Int J Oncol; 2015 Mar; 46(3):1259-67. PubMed ID: 25572009
[TBL] [Abstract][Full Text] [Related]
3. Roscovitine triggers apoptosis in B-cell chronic lymphocytic leukemia cells with similar efficiency as combinations of conventional purine analogs with cyclophosphamide.
Zolnierczyk JD; Błoński JZ; Robak T; Kiliańska ZM; Wesierska-Gadek J
Ann N Y Acad Sci; 2009 Aug; 1171():124-31. PubMed ID: 19723046
[TBL] [Abstract][Full Text] [Related]
4. R-roscovitine (Seliciclib) affects CLL cells more strongly than combinations of fludarabine or cladribine with cyclophosphamide: Inhibition of CDK7 sensitizes leukemic cells to caspase-dependent apoptosis.
Rogalińska M; Błoński JZ; Komina O; Góralski P; Zołnierczyk JD; Piekarski H; Robak T; Kiliańska ZM; Wesierska-Gadek J
J Cell Biochem; 2010 Jan; 109(1):217-35. PubMed ID: 19911397
[TBL] [Abstract][Full Text] [Related]
5. Can ex vivo evaluation (testing) predict the sensitivity of CLL cells to therapy with purine analogs in conjunction with an alkylating agent? A comparison of in vivo and ex vivo responses to treatment.
Żołnierczyk JD; Komina O; Błoński JZ; Borowiak A; Cebula-Obrzut B; Smolewski P; Robak P; Kiliańska ZM; Węsierska-Gądek J
Med Oncol; 2012 Sep; 29(3):2111-26. PubMed ID: 22086735
[TBL] [Abstract][Full Text] [Related]
6. Determination of the in vivo effects of cladribine alone and its combination with cyclophosphamide or cyclophosphamide and mitoxantrone on Bax and Bcl-2 protein expression in B-CLL cells.
Kobylinska A; Blonski JZ; Hanausek M; Walaszek Z; Robak T; Kilianska ZM
Oncol Rep; 2004 Mar; 11(3):699-705. PubMed ID: 14767525
[TBL] [Abstract][Full Text] [Related]
7. In vitro sensitivity of B-cell chronic lymphocytic leukemia to cladribine and its combinations with mafosfamide and/or mitoxantrone.
Kobylinska A; Bednarek J; Blonski JZ; Hanausek M; Walaszek Z; Robak T; Kilianska ZM
Oncol Rep; 2006 Dec; 16(6):1389-95. PubMed ID: 17089066
[TBL] [Abstract][Full Text] [Related]
8. Comparison of cladribine plus cyclophosphamide with fludarabine plus cyclophosphamide as first-line therapy for chronic lymphocytic leukemia: a phase III randomized study by the Polish Adult Leukemia Group (PALG-CLL3 Study).
Robak T; Jamroziak K; Gora-Tybor J; Stella-Holowiecka B; Konopka L; Ceglarek B; Warzocha K; Seferynska I; Piszcz J; Calbecka M; Kostyra A; Dwilewicz-Trojaczek J; Dmoszyñska A; Zawilska K; Hellmann A; Zdunczyk A; Potoczek S; Piotrowska M; Lewandowski K; Blonski JZ
J Clin Oncol; 2010 Apr; 28(11):1863-9. PubMed ID: 20212251
[TBL] [Abstract][Full Text] [Related]
9. Calorimetric study as a potential test for choosing treatment of B-cell chronic lymphocytic leukemia.
Rogalinska M; Goralski P; Wozniak K; Bednarek JD; Blonski JZ; Robak T; Piekarski H; Hanausek M; Walaszek Z; Kilianska ZM
Leuk Res; 2009 Feb; 33(2):308-14. PubMed ID: 18676014
[TBL] [Abstract][Full Text] [Related]
10. Mechanisms of action of the anti-VEGF monoclonal antibody bevacizumab on chronic lymphocytic leukemia cells.
Bogusz J; Majchrzak A; Mędra A; Cebula-Obrzut B; Robak T; Smolewski P
Postepy Hig Med Dosw (Online); 2013 Mar; 67():107-18. PubMed ID: 23475487
[TBL] [Abstract][Full Text] [Related]
11. Promising anti-leukemic activity of atorvastatin.
Żołnierczyk JD; Borowiak A; Hikisz P; Cebula-Obrzut B; Błoński JZ; Smolewski P; Robak T; Kiliańska ZM
Oncol Rep; 2013 May; 29(5):2065-71. PubMed ID: 23440293
[TBL] [Abstract][Full Text] [Related]
12. In vitro evaluation of fludarabine in combination with cyclophosphamide and/or mitoxantrone in B-cell chronic lymphocytic leukemia.
Bellosillo B; Villamor N; Colomer D; Pons G; Montserrat E; Gil J
Blood; 1999 Oct; 94(8):2836-43. PubMed ID: 10515887
[TBL] [Abstract][Full Text] [Related]
13. Cytotoxic effect of R-etodolac (SDX-101) in combination with purine analogs or monoclonal antibodies on ex vivo B-cell chronic lymphocytic leukemia cells.
Robak P; Linke A; Cebula B; Robak T; Smolewski P
Leuk Lymphoma; 2006 Dec; 47(12):2625-34. PubMed ID: 17169808
[TBL] [Abstract][Full Text] [Related]
14. Bax expression correlates with cellular drug sensitivity to doxorubicin, cyclophosphamide and chlorambucil but not fludarabine, cladribine or corticosteroids in B cell chronic lymphocytic leukemia.
Bosanquet AG; Sturm I; Wieder T; Essmann F; Bosanquet MI; Head DJ; Dörken B; Daniel PT
Leukemia; 2002 Jun; 16(6):1035-44. PubMed ID: 12040435
[TBL] [Abstract][Full Text] [Related]
15. Rituximab plus fludarabine and cyclophosphamide or other agents in chronic lymphocytic leukemia.
Robak T; Lech-Maranda E; Robak P
Expert Rev Anticancer Ther; 2010 Oct; 10(10):1529-43. PubMed ID: 20942624
[TBL] [Abstract][Full Text] [Related]
16. The cytotoxic activity of Aplidin in chronic lymphocytic leukemia (CLL) is mediated by a direct effect on leukemic cells and an indirect effect on monocyte-derived cells.
Morande PE; Zanetti SR; Borge M; Nannini P; Jancic C; Bezares RF; Bitsmans A; González M; Rodríguez AL; Galmarini CM; Gamberale R; Giordano M
Invest New Drugs; 2012 Oct; 30(5):1830-40. PubMed ID: 21887502
[TBL] [Abstract][Full Text] [Related]
17. Synergistic Activity of Deguelin and Fludarabine in Cells from Chronic Lymphocytic Leukemia Patients and in the New Zealand Black Murine Model.
Rebolleda N; Losada-Fernandez I; Perez-Chacon G; Castejon R; Rosado S; Morado M; Vallejo-Cremades MT; Martinez A; Vargas-Nuñez JA; Perez-Aciego P
PLoS One; 2016; 11(4):e0154159. PubMed ID: 27101369
[TBL] [Abstract][Full Text] [Related]
18. Entinostat combined with Fludarabine synergistically enhances the induction of apoptosis in TP53 mutated CLL cells via the HDAC1/HO-1 pathway.
Zhou Z; Fang Q; Li P; Ma D; Zhe N; Ren M; Chen B; He Z; Wang J; Zhong Q; Wang J
Life Sci; 2019 Sep; 232():116583. PubMed ID: 31226417
[TBL] [Abstract][Full Text] [Related]
19. Modulation of IL-4 level by fludarabine and its relation to apoptosis in chronic B-cell lymphocytic leukemia.
Shamaa LA; Hussein Ael-S; Balbaa OA; Farahat NM; Ali MA
Egypt J Immunol; 2008; 15(1):181-92. PubMed ID: 20306682
[TBL] [Abstract][Full Text] [Related]
20. Resveratrol increases rate of apoptosis caused by purine analogues in malignant lymphocytes of chronic lymphocytic leukemia.
Podhorecka M; Halicka D; Klimek P; Kowal M; Chocholska S; Dmoszynska A
Ann Hematol; 2011 Feb; 90(2):173-83. PubMed ID: 20714724
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
